Skip to content

Improving Diagnosis and Prediction of Outcome in Patients With Severe Disorders of Consciousness

Improving Diagnosis and Prediction of Outcome in Patients With Severe Disorders of Consciousness

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06283901
Acronym
IMPROVE-DOC
Enrollment
160
Registered
2024-02-28
Start date
2023-01-02
Completion date
2025-09-01
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Encephalitis, Intracranial Hemorrhages, Meningitis, Stroke, Subarachnoid Hemorrhage, Traumatic Brain Injury

Brief summary

Patients with acute severe brain injury are usually admitted to the Intensive Care Unit. A substantial proportion of these patients will have disorders of consciousness (DOC) after interruption of sedation. It is difficult to reliably predict neurological outcome in these patients. Dependent on the extent of permanently damaged brain areas, DOC in patients with acute severe brain injury may improve or persist, eventually evolving into a minimal conscious state (MCS) or unresponsive wakefulness syndrome (UWS). These conditions are accompanied by long term severe disability. In current practice, the decision to withdraw life-sustaining support is made by interpreting the results of repeated bedside neurological examination and conventional CT-brain imaging. Reliable identification of patients with a possible good outcome, in whom treatment should not be withdrawn, is difficult. In this prospective observational cohort study we aim to identify patients with a good neurological outcome.

Detailed description

In order to identify patients with a good neurological outcome a combination of diagnostic tests is used. Clinical rating scales * Simplified evaluation of consciousness scale (SECONDs) and the full outline of unresponsiveness (FOUR) score * Once a week Blood biomarkers * Neuron specific enolase, neurofilament light, glial fibrillary acidic protein * Sampling timepoints: 24h, 72h, 7 days and 14 days after brain injury * Serum (STG-5) and plasma (EDTA-6) tubes, aliquoted (4 x 0.5ml) and stored at -80°C EEG with reactivity testing * Standard 21-electrode montage * Stimuli protocol I: a set of 5 stimuli repeated 3 times 1\. Auditory: clapping in hands, 2. Auditory: calling patients name loudly, 3. Visual: passive eye opening, 4. Tactile: nasal tickle, 5. Noxious: sternal rub Each stimuli is applied for a duration of 5 seconds and an interval between stimuli of 30 seconds * Stimuli protocol II: Cognitive-motor dissociation test MRI-scan * Sequences considered essential for patient care i.e.T1, T2, FLAIR, DWI/SWI * Preferably, performed between 4-6 weeks after hospital admission

Interventions

None listed

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

All patients that are admitted to the ICU with the following criteria will be eligible for inclusion: 1. Severe brain injury (GCS ≤ 8) as a result of: 1. Traumatic brain injury 2. Ischemic cerebrovascular accident 3. Intracranial hemorrhage 4. Meningo-encephalitis 5. Subarachnoid hemorrhage 2. Age ≥ 18 years old 3. Written informed consent from legal representatives

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study: * Absence of informed consent * Moribund at ICU admission * Progressive neurodegenerative disease * Pre-admission life expectancy ≤ 6 months based on comorbidity * GCS has been \> 8 prior to inclusion * Impossible to include within 24 hours after brain injury

Design outcomes

Primary

MeasureTime frame
Glasgow Outcome Scale Extended6 months

Secondary

MeasureTime frame
Glasgow Outcome Scale Extended12 months

Countries

Netherlands

Contacts

Primary ContactWolmet Haksteen, MD
w.e.haksteen@amsterdamumc.nl+31 020 566 9111
Backup ContactJanneke Horn, Prof. dr.
j.horn@amsterdamumc.nl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026